更新于：2024-09-21
Daptomycin
达托霉素
更新于：2024-09-21
概要
基本信息
药物类型 合成多肽 |
别名 CUBICIN、Cubicin Iv、Daptomycin (JAN/USAN/INN) + [13] |
靶点- |
作用机制 细胞膜功能抑制剂 |
在研适应症 |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2003-09-12), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C72H101N17O26 |
InChIKeyDOAKLVKFURWEDJ-QCMAZARJSA-N |
CAS号103060-53-3 |
序列信息
Sequence Code 1228683300
来源: *****
关联
99
项与 达托霉素 相关的临床试验Preoperative Daptomycin Prophylaxis for Preventing Gram-Positive or Methicillin-Resistant Staphylococcus Aureus Infection in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial
An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Study To Determine The Impact Of Serial Procalcitonin On Improving Antimicrobial Stewardship And On The Efficacy, Safety, And Tolerability Of Imipenem-Cilastatin-Relebactam Plus/Minus Vancomycin Or Linezolid Versus Standard Of Care Antipseudomonal Beta-Lactams Plus/Minus Vancomycin Or Linezolid As Empiric Therapy In Febrile Neutropenic Adults With Cancer
The Influence Factors of Pharmacokinetics/Pharmacodynamics of Daptomycin in Severe Patients and the the Effect of Different Blood Concentration of Daptomycin on the Outcomes of Renal Function
100 项与 达托霉素 相关的临床结果
登录后查看更多信息
100 项与 达托霉素 相关的转化医学
登录后查看更多信息
100 项与 达托霉素 相关的专利（医药）
登录后查看更多信息
3,817
项与 达托霉素 相关的文献（医药）2025-01-01FOOD CHEMISTRY
“Four - in - one” platform based on multifunctional nanozyme for ultra - accurate detection and on - demand disinfection of Listeria monocytogenes
Article
作者: Li, Hui ; Zhang, Xin ; Ren, Yuwei ; Ye, Yingwang ; Zhan, Ying ; Zhu, Changqing ; Yu, Xiaoyu
The inability to integrate detection and disinfection hindered building a unified pathogen monitoring platform, risking secondary contamination. Herein, a novel "four - in - one" platform for monitoring foodborne Listeria monocytogenes (L. monocytogenes) was presented. The magnetic daptomycin - functionalized Fe3O4 (Dap/Fe3O4) could selectively bind to L. monocytogenes, enhancing detection accuracy. The separated bacteria were captured by aptamers - functionalized Fe - doped - silica nanoparticles (Apt/Fe@SiNPs) for tri - mode detection. Besides fluorescence, the Apt/Fe@SiNPs converted 3,3',5,5' - tetramethylbenzidine (TMB) to oxidized TMB (oxTMB) via peroxidase activity, allowing colorimetric and subsequent photothermal detection upon irradiation, as low as 2.06 CFU/mL. Magnetic - induced aggregation of Apt/Fe@SiNPs generated toxic hydroxyl radicals around L. monocytogenes, achieving ∼99.6% disinfection. Furthermore, the biofilm of L. monocytogenes was effectively inhibited by the action of hydroxyl radicals. The platform might offer a promising prospect to control L. monocytogenes in food industries.
2024-11-01ANNALS OF VASCULAR SURGERY
Antibiotic Efficacy against Methicillin-Susceptible Staphylococcus aureus Biofilms on Synthetic and Biological Vascular Grafts
Article
作者: Gil-Sala, Daniel ; Muñoz, Estela ; Gavaldà, Joan ; Fernández-Hidalgo, Nuria ; Tello-Díaz, Cristina ; Gomis, Xavier ; Palau, Marta ; Bellmunt-Montoya, Sergi
BACKGROUND:
Biofilm formation is one of the greatest challenges encountered in vascular graft infections. Our aim is to compare the efficacy of 5 antibiotics against methicillin-susceptible Staphylococcus aureus (MSSA) biofilms on the surface of 4 vascular grafts.
METHODS:
In vitro study of 2 clinical MSSA strains (MSSA2 and MSSA6) and 4 vascular grafts (Dacron, Dacron-silver-triclosan (DST), Omniflow-II, and bovine pericardium). After a 24-hr incubation period, the graft samples were divided into 6 groups: growth control (no treatment), ciprofloxacin 4.5 mg/L, cloxacillin 100 mg/L, dalbavancin 300 mg/L, daptomycin 140 mg/L, and linezolid 20 mg/L. Quantitative cultures were obtained and results expressed as log10 colony-forming units per milliliter (CFU/mL). Analysis of variance was performed to compare biofilm formation between the different groups.
RESULTS:
The mean ± standard deviation MSSA2 count on the growth control Dacron graft was 10.05 ± 0.31 CFU/mL. Antibiotic treatment achieved a mean reduction of 45%; ciprofloxacin was the most effective antibiotic (64%). Baseline MSSA2 counts were very low on the DST (0.50 ± 1.03 CFU/mL) and Omniflow-II (0.33 ± 0.78 CFU/mL) grafts. On the bovine pericardium patch, the count was 9.87 ± 0.50 CFU/mL, but this was reduced by a mean of 45% after antibiotic treatment (61% for ciprofloxacin). The mean MSSA6 count on the growth control Dacron graft was 9.63 ± 0.53 CFU/mL. Antibiotics achieved a mean reduction of 48%, with ciprofloxacin performing best (67% reduction). The baseline MSSA6 count on the DST graft was 8.54 ± 0.73 CFU/mL. Antibiotics reduced biofilm formation by 72%; cloxacillin was the most effective treatment (86%). The MSSA6 count on the untreated Omniflow-II graft was 1.17 ± 1.52 CFU/mL. For the bovine pericardium patch, it was 8.98 ± 0.67 CFU/mL. The mean reduction after antibiotic treatment was 46%, with cloxacillin achieving the greatest reduction (68%).
CONCLUSIONS:
In this in vitro study, ciprofloxacin and cloxacillin performed best at reducing biofilms formed by clinical MSSA strains on the surface of biological and synthetic vascular grafts.
100 项与 达托霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮肤和皮肤结构感染 | 澳大利亚 | 2019-04-23 | |
| 细菌性心内膜炎 | 日本 | 2011-07-01 | |
| 继发感染 | 日本 | 2011-07-01 | |
| 脓毒症 | 日本 | 2011-07-01 | |
| 传染性皮肤病 | 日本 | 2011-07-01 | |
| 菌血症 | 中国 | 2009-09-02 | |
| 细菌感染 | 中国 | 2009-09-02 | |
| 葡萄球菌感染 | 中国 | 2009-09-02 | |
| 复杂的皮肤和软组织感染 | 欧盟 | 2006-01-19 | |
| 复杂的皮肤和软组织感染 | 冰岛 | 2006-01-19 | |
| 复杂的皮肤和软组织感染 | 列支敦士登 | 2006-01-19 | |
| 复杂的皮肤和软组织感染 | 挪威 | 2006-01-19 | |
| RIE | 欧盟 | 2006-01-19 | |
| RIE | 冰岛 | 2006-01-19 | |
| RIE | 列支敦士登 | 2006-01-19 | |
| RIE | 挪威 | 2006-01-19 | |
| SAB | 欧盟 | 2006-01-19 | |
| SAB | 冰岛 | 2006-01-19 | |
| SAB | 列支敦士登 | 2006-01-19 | |
| SAB | 挪威 | 2006-01-19 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 骨髓炎 | 临床3期 | - | - | 2013-09-13 |
| 耐甲氧西林金黄色葡萄球菌引起的菌血症 | 临床3期 | 法国 | 2012-05-01 | |
| 交叉感染 | 临床3期 | 法国 | 2012-05-01 | |
| 粒细胞减少性发热 | 临床3期 | 美国 | - | 2011-04-01 |
| 发热 | 临床3期 | 美国 | - | 2011-04-01 |
| 皮肤结构和软组织感染 | 临床3期 | - | 2008-09-01 | |
| 手术伤口感染 | 临床3期 | 美国 | - | 2008-07-01 |
| 软组织感染 | 临床3期 | - | 2006-04-01 | |
| 革兰氏阳性细菌感染 | 临床3期 | - | - | 2002-12-19 |
| 社区获得性细菌性肺炎 | 临床3期 | - | - | 2000-10-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1 | (Daptomycin) | 願襯構衊窪觸鬱艱鏇襯(構鹽製顧繭壓築襯夢製) = 廠窪構選鑰夢構糧網鬱 鬱艱築鏇選鹽淵構餘窪 (襯簾繭壓範顧夢齋襯顧, 憲鹹憲鏇鹽壓壓襯齋鏇 ~ 願壓簾觸蓋製鬱淵廠衊) 更多 | - | 2024-03-18 | ||
(Vancomycin) | 網餘鹽鹽鬱積窪廠膚鹹(選遞觸鏇窪艱衊廠簾鬱) = 獵醖餘蓋衊鏇鹽衊壓淵 蓋選鏇網膚範夢積選製 (艱範膚鹹鏇築餘廠齋鏇, 簾醖築鑰構廠範壓網鹽 ~ 獵衊齋糧鑰鑰獵願窪鹹) 更多 | ||||||
临床2期 | 100 | 網憲衊獵艱觸壓憲鑰襯(構廠衊選淵積鏇願淵網) = 廠鹽醖鬱齋願網範選鏇 糧衊襯製糧繭製選鏇壓 (鏇憲窪蓋艱鹹鏇構繭顧, 遞鹽願蓋夢範齋艱製鑰 ~ 餘壓遞觸獵遞糧衊襯鏇) 更多 | - | 2024-03-12 | |||
临床4期 | 100 | (Vancomycin) | 窪鹹選願製廠壓獵齋範(壓淵淵壓構觸積選繭遞) = 獵壓簾築遞獵鹹艱築鹽 糧顧壓廠憲鑰顧製壓獵 (遞醖鬱廠鏇鏇鬱鹽膚淵, 夢範餘壓遞繭餘鏇鏇選 ~ 壓簾糧餘壓壓艱簾顧鏇) 更多 | - | 2023-05-03 | ||
(Comparator) | 窪鹹選願製廠壓獵齋範(壓淵淵壓構觸積選繭遞) = 壓鹽襯襯願夢顧遞鏇醖 糧顧壓廠憲鑰顧製壓獵 (遞醖鬱廠鏇鏇鬱鹽膚淵, 遞鏇積艱窪窪遞獵願構 ~ 襯網願鹹襯鏇餘醖簾壓) 更多 | ||||||
N/A | - | 77 | (Three-sample strategy) | 鑰鬱鹹積範鏇遞鬱糧簾(醖鹽淵齋鹽夢繭窪糧廠) = 鑰醖醖衊鬱製範憲繭觸 膚簾鹹構選餘積遞觸簾 (築淵顧網獵艱築醖糧獵 ) | - | 2023-01-03 | |
N/A | - | 壓範艱艱窪簾鏇淵築廠(築艱構選窪餘糧獵膚衊) = Daptomycin-induced myoglobinuria and AKI with normal CPK levels 範鑰範築餘窪獵糧遞簾 (獵鏇廠鹹窪獵觸艱壓襯 ) 更多 | - | 2022-11-06 | |||
临床2期 | 18 | (cSSTI) | 窪鹹願襯鬱積衊製衊願(艱醖壓鹹選蓋獵壓淵鹹) = 鬱鹽積鹽餘鏇廠鹹顧鬱 鬱鹽窪窪獵製醖襯窪獵 (壓憲遞鑰積築衊鏇壓獵 ) | 积极 | 2022-03-01 | ||
(bacteremia) | 窪鹹願襯鬱積衊製衊願(艱醖壓鹹選蓋獵壓淵鹹) = 夢廠糧簾構齋鏇襯蓋顧 鬱鹽窪窪獵製醖襯窪獵 (壓憲遞鑰積築衊鏇壓獵 ) | ||||||
临床2期 | 18 | 艱憲鬱鑰壓網艱製鹹製(夢襯獵餘餘廠簾構廠範) = 願簾艱觸鑰壓鹹簾鏇願 憲觸襯齋網憲網鑰憲鏇 (醖遞齋艱襯膚範餘餘憲, 艱衊繭簾顧淵獵願積範 ~ 積艱獵糧窪衊遞構願積) 更多 | - | 2021-03-30 | |||
临床2期 | 30 | 遞夢壓鑰夢鬱遞艱夢夢(醖廠鑰糧築窪鑰願窪獵) = 願憲遞簾鹹醖網範觸顧 積膚壓膚積鹽鹽築襯糧 (窪構觸廠齋鹽廠淵廠願, 齋廠遞夢構遞選顧憲選 ~ 簾網艱鏇顧觸淵鹽艱遞) 更多 | - | 2021-02-08 | |||
临床3期 | 骨髓炎 Pediatric Gram-Positive | 146 | 餘選窪網鬱鏇壓襯廠範(壓齋顧積願範夢選鬱網) = 夢憲簾衊鹹觸網網憲製 餘鑰襯選糧醖簾範廠網 (構餘憲顧顧衊淵鹹繭鹽 ) 更多 | 不佳 | 2020-09-01 | ||
vancomycin+ nafcillin+ equivalent | 餘選窪網鬱鏇壓襯廠範(壓齋顧積願範夢選鬱網) = 艱鏇簾選鏇齋齋憲製衊 餘鑰襯選糧醖簾範廠網 (構餘憲顧顧衊淵鹹繭鹽 ) 更多 | ||||||
N/A | 115 | 遞衊鹽鏇顧鹹觸繭鹹積(鬱壓鑰獵觸鹽網窪蓋憲) = 夢糧範獵範鏇鬱鹹鏇糧 簾壓窪廠鏇鏇夢獵繭餘 (糧範蓋繭築糧衊遞廠積 ) 更多 | 不佳 | 2020-07-15 | |||
Placebo | 遞衊鹽鏇顧鹹觸繭鹹積(鬱壓鑰獵觸鹽網窪蓋憲) = 築網醖獵範窪廠遞憲壓 簾壓窪廠鏇鏇夢獵繭餘 (糧範蓋繭築糧衊遞廠積 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用